Stage 4: GFR 29-15

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity

Protocol Name: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Sponsor: Eli Lilly Indication: CVD and CKD Outcomes in patients with Obesity Principal Investigator:Bernard Fischbach, MD Location:Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Read More »

Observational Study Protocol – Fabry Disease Registry

Protocol Name: Observational Study Protocol – Fabry Disease Registry Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Observational Study Protocol – Fabry Disease Registry Read More »

Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease (Amicus)

Protocol Name: A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease Sponsor: Amicus Indication: Fabry Disease Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease (Amicus) Read More »

Phase 2/​3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (Vertex)

Protocol Name: Phase 2/​3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease Sponsor: Vertex Indication: APOL1-Mediated Proteinuric Kidney Disease Primary Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

Phase 2/​3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (Vertex) Read More »